Evaluation of the Effect of deferasirox on the treatment of ??Acute myeloid leukemia

Phase 3

• Conditions: Acute myeloblastic leukemia.; Acute myeloblastic leukemia; C92.0

• Registration Number: IRCT20200313046756N2
• Lead Sponsor: Kerman University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 29 August 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Age between 18-65 years
AML/non-AP

Exclusion Criteria

HIV infected patients or Hepatitis B,C patients
Patients with AML-induced neurological involvement
Patients with uncontrolled blood pressure and heart failure
Patients with a history of ocular toxicity due to iron chelators drugs

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The number of white blood cells. Timepoint: on days 14 and 28. Method of measurement: Test for complete blood cell count.;Number of red blood cells. Timepoint: on days 14 and 28. Method of measurement: Test for complete blood cell count.;Platelet numbers. Timepoint: on days 14 and 28. Method of measurement: Test for complete blood cell count.;Percentage of CD34 + leukemia blasts of bone marrow biopsy specimen. Timepoint: on days 14 and 28. Method of measurement: Flow cytometry with CD34 monoclonal antibody.

Secondary Outcome Measures

Name	Time	Method
Reactive oxygen species rate in +CD34 leukemic blasts bone marrow biopsy sample. Timepoint: on days 14 and 28. Method of measurement: Flow cytometry.;The rate of apoptotic cells in +CD34 leukemic blasts bone marrow biopsy sample. Timepoint: on days 14 and 28. Method of measurement: Flow cytometry.